Our business ethos is unique: Our revenues serve the National Health Service and St George’s University of London, fund basic research, support charities or otherwise are reinvested in the business. Our business is sustainable, adaptive to change and is led by the same specialists who founded the business more than ten years ago.
All our sponsors are preferred clients. Richmond Pharmacology’s interaction with its sponsors is personal and truly strategic, generating enhanced value for drug developers and investors.
Our work is closely supervised throughout by the same senior specialists sponsors meet during the first consultation or bid defence. Our services span strategic consultancy and concept development through to final reporting, utilising our many years of experience and leading to successful clinical trials with meaningful results.
Richmond Pharmacology is constantly assessing health and safety risks posed by COVID-19 and is regularly reviewingRead more ›
Richmond Pharmacology are continuously risk-assessing our activity in relation to the COVID-19 crisis and we areRead more ›
The US Food and Drug Administration (FDA) has officially approved a transdermal patch to treat schizophreniaRead more ›